New insider activity at United Therapeutics ( (UTHR) ) has taken place on September 25, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Christopher Causey has recently sold 1,000 shares of United Therapeutics stock, amounting to a total transaction value of $440,000.
Recent Updates on UTHR stock
In the last 24 hours, United Therapeutics has seen significant positive developments, primarily driven by promising results from its TETON-2 trial for Tyvaso in treating idiopathic pulmonary fibrosis (IPF). This has led to multiple analysts raising their price targets for the company. Cantor Fitzgerald increased its target due to the de-risking of IPF, while Oppenheimer noted the potential for Tyvaso to generate substantial sales by 2033, supported by statistically significant trial results. H.C. Wainwright highlighted Tyvaso’s consistent benefits across various patient subgroups, and UBS emphasized the successful Phase 3 readout as a positive surprise, suggesting further upside potential. Overall, the positive trial outcomes have bolstered confidence in Tyvaso’s market potential, significantly impacting United Therapeutics’ stock outlook.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
United Therapeutics’ strong financial performance and strategic initiatives, including record revenue growth and a significant share buyback, are major strengths. The technical indicators suggest bullish momentum, though potential overbought conditions warrant caution. The company’s reasonable valuation and promising pipeline developments further support a positive outlook, despite competitive and regulatory challenges.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
YTD Price Performance: 21.80%
Average Trading Volume: 719,270
Technical Sentiment Signal: Buy
Current Market Cap: $19.84B